50 results about "Immune cell infiltration" patented technology

The invention relates to an immune gene prognosis model for predicting hepatocellular carcinoma tumor immune infiltration and postoperative survival time, and belongs to the technical field of biological medicines. The model can be used for evaluating the infiltration degree of immune cells in a tumor in clinical practice by detecting the expression levels of 22 specific immune related genes of ahepatocellular carcinoma patient, so that the model can be used for predicting hepatocellular carcinoma tumor immune infiltration in clinical practice and improve the prediction capability of the liver cancer immunotherapy response. The model can be used for judging the postoperative overall survival risk of a patient and guiding the formulation of a postoperative treatment strategy, and the corresponding microarray chip kit can realize the standardization and convenience of detection. Meanwhile, the immune gene prognosis model provided by the invention can increase the prediction accuracy andthe clinical net income of a hepatocellular carcinoma TNM staging system on the total survival time of three years and five years after operation. As a molecular marker for objectively and accuratelyevaluating the tumor immune state and poor prognosis risk of hepatocellular carcinoma, the model can realize accurate implementation of hepatocellular carcinoma immunotherapy and accurate prognosis prediction.

Methods included herein describe the treatment of a tumor by administering dendritic cells either directly into the same or into its surrounding tissue. Further methods describe the induction of immune cell infiltration into tumors and the treatment of tumors with unprimed dendritic cells by administering dendritic cells in a similar fashion. The methods of the present invention are particularly advantageous in the treatment of brain tumors and other solid tumors disposed throughout the body of a mammal that are difficult or impossible to treat by conventional surgical means. Dendritic cell-based compositions effective in the treatment of such tumors are also described.

This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication.

The invention provides a genetically engineered cell membrane nano vesicle and preparation and an application thereof. The nano vesicle is composed of biological cell membranes, and the surface is transferred with a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a programmed death receptor 1 (PD-1), and internal entrapment catalase (CAT). TRAIL can specifically induce tumor celldeath, release tumor antigens and "dangerous signal molecules", and triggers an immune response; the PD-1 can combines PD-L1 protein on cancer cells, and blocks related immunosuppressive pathways; andthe CAT can catalyze H2O2 of a tumor site to produce oxygen, improves a tumor hypoxic environment, and enhances infiltration of immune cells. Through organic integration of the functions, effective elimination of tumor cells and rapid activation of an autoimmune system are achieved, and a multi-point synergistic anti-tumor effect is exerted.

The invention provides a water-in-oil-water type vaccine adjuvant and application thereof. According to the technical scheme, ingredients which conform to large production demands and have immunopotentiation are preferred, according to a controlled release principle of a water-in-oil-water type microsphere, an adding mode is designed, thus the water-in-oil-water type vaccine adjuvant more effectively directly acts on an immune cell, and the immune potency is improved. Compared with an regular adjuvant in the prior art, the prepared water-in-oil-water type vaccine adjuvant has reasonable controlled release, target and an isolation characteristic, and after poultry is injected with a vaccine, the water-in-oil-water type microsphere timely metabolizes and breaks so as to comprehensively motivate a poultry lymphocyte to generate an antibody. An immune reinforcing agent with a heavy water phase can be lastingly and slowly release in a subsequent immune cell infiltration process to make bioavailability of the immune reinforcing agent maximize, it is shown that an injected part is well absorbed, an injected animal fast generates immunoprotection, and not only short-term immunity can be induced, but also long-term immunity can be induced.

The invention discloses an analysis method of an immune prognosis diagnosis marker combination for the ovarian cancer. The marker combination comprises the following genes: CSPG5, CXCL10, CXCL11, DKK1, PI3, TNFRSF17, DUOX1, TNFRSF13B and PAEP. The analysis method comprises the following steps of: S1, collecting and preprocessing data; S2, performing TMB score calculation and prognosis analysis; S3, performing difference analysis; S4, constructing and evaluating a TMB-immune prognosis related risk scoring model; S5, determining the relationship between clinical pathological factors and the TMB-IRS model; S6, carrying out CIBERSORT database analysis; and S7, carrying out statistical analysis. According to the analysis method, the immune risk scoring model related to TMB is constructed through nine key tumor mutation load related immune prognosis genes of the ovarian cancer, patients are divided into a high-risk group and a low-risk group, and it is proved that the high-risk group is related to poor prognosis, and the immune cell infiltration proportion of the patients in the low-risk group is higher; and prognosis prompts are provided for clinical treatment of the ovarian cancer, and the marker combination can be used as a novel biomarker and a potential treatment target for predicting ovarian cancer prognosis.

Immune context scores are calculated for tumor tissue samples using continuous scoring functions. Feature metrics for at least one immune cell marker are calculated for a region or regions of interest, the feature metrics including at least a quantitative measure of human CD3 or total lymphocyte counts. A continuous scoring function is then applied to a feature vector including the feature metric and at least one additional metric related to an immunological biomarker, the output of which is an immune context score. The immune context score may then be plotted as a function of a diagnostic or treatment metric, such as a prognostic metric (e.g. overall survival, disease-specific survival, progression-free survival) or a predictive metric (e.g. likelihood of response to a particular treatment course). The immune context score may then be incorporated into diagnostic and / or treatment decisions.

Provided relates to the field of cytometry, specifically to flow cytometric methods and kits for improved diagnosis, prognosis and monitoring of tumors and other lesions involving immune cell infiltration. Further provided are embodiments of the subject matter which relate to compositions and methods providing high resolution quantitative means for immunophenotyping and immune modeling, and for identification of disease prognostic and therapy predictive biomarkers.

The invention relates to the technical field of bio-medicine, in particular to application of PINK1 serving as a diagnostic marker in construction of a lung squamous cell carcinoma prognosis prediction model. The biomarker PINK1 and other clinical indexes are used in a combined mode, and lung squamous cell carcinoma prognosis detection can be assisted. According to the invention, screening and construction are carried out after full transcriptome sequencing and machine learning of a lung squamous cell carcinoma specimen based on large-sample anti-tumor immuno-therapy, so that the prognosis condition of a lung squamous cell carcinoma patient can be efficiently and accurately predicted; and meanwhile, according to the correlation between the risk and different immune cell infiltration levels, immune-related pathways, key immune checkpoint inhibitor expression levels and the like, comprehensive evaluation of the tumor immune micro-environment is achieved, effective guidance is provided for clinicians to make a treatment decision on lung squamous cell carcinoma patients, invalid treatment is reduced, and therefore, the treatment cost and discomfort experience of the patients are reduced.

The invention discloses an application of minocycline hydrochloride to preparation of a medicine for treating autoimmune uveitis and a treatment method of the autoimmune uveitis. The inventor finds that the minocycline hydrochloride can be used as an early intervention medicine by exploring the treatment effect of minocycline with different administration dosages on the autoimmune uveitis. By inhibiting microglial cell activation of retina tissue, reducing immune cell infiltration and reconstructing a steady state in gastrointestinal tract flora, generation and development of the uveitis are effectively inhibited, a new application is provided for application of the minocycline hydrochloride, and besides, a new strategy and method are provided for early prevention and intervention of the autoimmune uveitis.

Immune context scores are calculated for stage IV colorectal tumor tissue samples using non-continuous scoring functions. Feature metrics for at least one immune cell marker are calculated for a region or regions of interest, the feature metrics including at least a density of human CD8+ cells in a region of interest including a tumor core to generate an immune context score. The immune context score can then be used as a predictive metric (e.g. likelihood of response to a particular treatment course). The immune context score may then be incorporated into diagnostic and / or treatment decisions.

The invention discloses an application of muscle stem cells in preparation of an anti-inflammatory drug. The muscle stem cells or the supernate thereof are mediated by anti-inflammatory macrophages, the anti-inflammatory characteristic is formed in the macrophage maturation process, and inflammatory diseases caused by inflammatory macrophages as main pathogenic cell populations can be effectivelytreated. For example, the disease symptoms of weight loss, diarrhea, hematochezia, intestinal tissue thickening and edema, structural damage and immune cell infiltration can be effectively relieved bytreating colitis mice with muscle stem cells or supernate thereof.

The invention discloses application of a compound Nib1, a pharmaceutically acceptable salt, a solvate, a solvate of the pharmaceutically acceptable salt or a crystal form thereof in preparation of a medicine for treating autoimmune skin diseases caused by inflammation, improving skin erythema, improving skin decrustation, reducing skin thickening, reducing epidermal hyperplasia, improving angiectasis and / or reducing immune cell infiltration. The chemical formula of the Nib1 is C28H29F2N3O. The compound provided by the invention is a new treatment mechanism aiming at autoimmune skin diseases (such as psoriasis diseases) caused by inflammation, is small in side effect and convenient in administration route, can achieve the balance of safety and effectiveness, can be used for a long time, andimproves the life quality of patients. The compound can significantly improve clinical symptoms of autoimmune skin diseases caused by inflammation, such as erythema cutanea, skin peeling, skin thickening, epidermal hyperplasia, improve angiectasis and reduce immune cell infiltration and the like.

The invention discloses a glutamine metabolism gene tag scoring system for predicting prognosis and treatment resistance of hepatocellular carcinoma, and belongs to the technical field of biological medicine. By detecting the expression level of seven specific glutamine metabolism related genes of a hepatocellular carcinoma patient, a model can be used for judging the total lifetime of the patient, evaluating the treatment resistance of a postoperative transcatheter arterial chemoembolism patient and evaluating the immune cell infiltration degree in a tumor and the immune escape potential of a tumor cell, and the prediction capability on the liver cancer immunotherapy reaction is improved. Meanwhile, the model provided by the invention can improve the prediction accuracy of the three-year total lifetime of hepatocellular carcinoma, and compared with the prediction of the prognosis of the patient directly through the existing next-generation sequencing technology, the number of genes needing to be detected is reduced, the efficiency is improved, and the cost is reduced. As a molecular marker capable of objectively and accurately evaluating hepatocellular carcinoma treatment resistance and tumor immune state, accurate prediction and precise implementation of hepatocellular carcinoma treatment prognosis can be realized.

The invention discloses a method for constructing a tumor mutation load TMB panel. The method comprises the following steps: 1) acquiring transcriptome data of a tumor patient, and dividing the transcriptome data into a high TMB group and a low TMB group; 2) screening immune-related differential expression genes DEGs between the high TMB group and the low TMB group, and carrying out enrichment analysis; 3) carrying out immune cell infiltration analysis through Immune CellAI, and screening out potential key immune cells; 4) screening out tumor immunity related genes for prognosis of the patient; 5) establishing modules with different colors and a correlation matrix of immune traits possibly influencing prognosis; and 6) selecting genes with better correlation with macrophages, DC, MAIT andinfiltration integration in the WCGNA, and preliminarily obtaining a TMBIF gene panel. The invention also provides a using method of the tumor mutation load TMB panel. The tumor mutation load TMB panel constructed by the invention is low in sequencing cost and low in DNA input requirement in use, has shorter turnover time, can perform deeper sequencing, and improves the mutation detection sensitivity.

The invention relates to application of PCDH11X mutation in predicting sensitivity of a non-small cell lung cancer patient to an immune checkpoint inhibitor therapy, as well as application of PCDH11X mutation in predicting tumor mutation load, DNA mismatch repair pathway gene mutation and in-tumor immune cell infiltration degree of the non-small cell lung cancer patient.

The invention provides a classification method and system of immune-related disease molecular typing and a subtype classifier, and the method comprises the steps: carrying out the molecular typing in a training set through a clustering algorithm, and obtaining a plurality of subtypes stably appearing in the training set and a marker gene of each subtype; carrying out enrichment analysis on marker genes of the subtypes, carrying out immune cell infiltration evaluation on the subtypes, and obtaining various subtype categories with stable immune characteristics according to analysis and evaluation results; comparing the treatment response rates of different subtype categories through the comparison set, and determining the subtype category needing to be recognized; constructing a support vector machine model by utilizing the feature genes obtained by screening and the optimal parameter combination; and identifying whether the to-be-classified immune-related disease data is a required subtype category or not. According to the invention, immune-related disease subtypes with stable characteristics can be identified, so that accurate drug selection and economic treatment are facilitated. The invention is applicable to molecular typing and subtype classification of various immune-related diseases, and is not limited to the embodiments herein.

The invention belongs to the technical field of tumor immunotherapy, and particularly relates to a CXCL9 modified chimeric antigen receptor T (CAR-T) structure and application patent application matter thereof. The CXCL9 modified CAR-T structure meso-CAR-CXCL9 has a specific structure: CD8a-meso-CD28-CD3Zeta-P2A-CXCL9. In the application, inventors obtain CAR-T-CXCL9 cells based on mesothelin design by taking a lung cancer model as an example. Preliminary experiment results show that, compared with conventional CAR-T cells, the modified cells have higher cytokine secretion and cytotoxicity capacities, can obviously increase immune cell infiltration of a tumor site, and inhibit angiogenesis, and further, the modified CAR-T-CXCL9 cell therapy slows down tumor growth, increases the survival rate of mice, and shows excellent anti-tumor activity.

The invention relates to the technical field of tumor treatment, in particular to a method for predicting tumor treatment prognosis by establishing an inflammatory cell infiltration model based on iconomics, and the method comprises the following steps: obtaining an immune infiltration proportion through patient genome data, and then performing iconomics analysis or neural network learning with corresponding iconomics data to obtain an immune infiltration model; an output result is a corresponding immune infiltration result, an immune cell infiltration model is established, finally, the model is used for predicting an image of a new patient, the infiltration condition of the new patient is obtained, and compared with a traditional method, the method has the advantages of being noninvasive, rapid, repeatable and the like; a completely noninvasive means is provided for judging immune change and prognosis conditions in the tumor disease treatment process.

The invention provides an application of an RPS3A molecule in prediction of immune cell infiltration and immune checkpoint molecular expression level in tumors and a prediction model. According to theinvention, the expression level of RPS3A in postoperative tumor tissues of a hepatocellular carcinoma patient is detected; in clinical practice, the RPS3A can be used as a molecular marker to reflectthe infiltration level of immune cells in tumors and the molecular expression condition of immune checkpoints and guide the immunotherapy management of liver cancer patients, so that the immunological characteristics and prognosis risk of hepatocellular carcinoma can be evaluated, the formulation of a liver cancer individualized treatment scheme can be promoted, and relatively high guiding significance is achieved; meanwhile, the Nomogram prognosis prediction model is constructed on the basis of RPS3A molecules, compared with traditional TNM and BCLC stages, better prediction efficiency and accuracy are achieved, liver cancer patients are enabled to obtain more clinical net income, and the RPS3A molecule can be applied to clinically and accurately judging the postoperative survival time of hepatocellular carcinoma patients.

Immune context scores are calculated for stage III colorectal tumor tissue samples using continuous scoring functions. Feature metrics for at least one immune cell marker are calculated for a region or regions of interest, the feature metrics including at least a density of human CD3+ cells in a region of interest including an invasive margin. A continuous scoring function is then applied to a feature vector, the output of which is an immune context score. The immune context score may then be plotted as a function of a diagnostic or treatment metric, such as a prognostic metric (e.g. overall survival, disease-specific survival, progression-free survival) or a predictive metric (e.g. likelihood of response to a particular treatment course). The immune context score may then be incorporated into diagnostic and / or treatment decisions.

The invention belongs to the technical field of biological medicines, and particularly relates to application of dental pulp stem cells in preparation of a medicine for treating multiple sclerosis. The embodiment of the invention provides application of dental pulp stem cells in preparation of a medicine for treating multiple sclerosis. The dental pulp stem cells are simple and convenient to obtain, easy to amplify in vitro and high in multiplication capacity, and have clinical application advantages compared with other human body mesenchymal stem cells. Research shows that the dental pulp stem cells can obviously reduce EAE mouse spinal cord demyelination focus, reduce the injury area around the ventricle and reduce demyelination injury; in addition, immune cell infiltration in the brain can be obviously reduced, T cell infiltration is reduced, and central inflammation is inhibited.

The present invention provides methods for increasing the sensitivity of a tumour to immunotherapy, chemotherapy or radiotherapy by administering an effective amount of an oligonucleotide that inhibits the binding of miR-27a, or a variant thereof, to its target mRNA. Oligonucleotides used in the invention are typically in the form of a blockmirs used as an adjunctive therapy to inhibit tumour growth, normalise and / or improve functions of tumour vasculature, and / or promote immune cell infiltration of tumours.

Described is a computer-implemented method for identifying responsiveness to therapy for a subject suffering from cancer. The method involves determining values of biomarkers such as the levels of TREX1, PD-L1 and / or immune cell infiltration in a cancerous lesion. The biomarker values are processed to obtain a score indicative of responsiveness of the cancerous lesion to combined radio- and immunotherapy treatment. The method may obtain scores for multiple treatment modalities (such as different doses and / or fractionations of radiotherapy) and / or different cancer lesions in the subject. Also provided is a system and computer program product for performing the method.

The invention relates to the technical field of biomedicine and particularly relates to application of RGS19 in construction of a lung squamous cell carcinoma prognosis prediction model as a diagnostic marker. According to the application, the biomarker RGS19 is used through being combined with other clinical indexes, and lung squamous cell carcinoma prognosis detection can be made in an assisted manner; screening and constructing are carried out after carrying out full-transcriptome sequencing and machine learning based on lung squamous cell carcinoma specimens subjected to large-sample antitumor immunotherapy, and prognosis conditions of a lung squamous cell carcinoma sufferer can be efficiently and accurately predicted; and meanwhile, comprehensive evaluation on an immunization microenvironment of a tumor is achieved according to correlation between the risk of the tumor and different immunized cell infiltration levels, immunization-related channels and key immunization check point inhibitor expression levels, so that an effective instruction opinion is provided for clinicians for therapy decision making for the lung squamous cell carcinoma sufferer, occurrence of invalid therapy is reduced, and thus, the therapy cost and discomfort experience of the sufferer are reduced.

The invention belongs to the technical field of biology, and relates to a breast cancer assisted immunotherapy target gene MARCHF1 detection kit and application. The research proves that the MARCHF1 expression in breast cancer is obviously increased. The MARCHF1 expression level is in positive correlation with immune microenvironment indexes StromalScore, ImmuneScore and ESTIMATEScore, is in positive correlation with infiltration of various immune cells, and is in positive correlation with gene expression of an immune checkpoint, and the MARCHF1 detection kit is designed, and the MARCHF1 expression level is in positive correlation with immune microenvironment indexes StromalScore, ImmuneScore and ESTIMATEScore.

The present invention relates to the role of PCDH11X mutations in predicting the sensitivity of non-small cell lung cancer patients to immune checkpoint inhibitor therapy, as well as in predicting tumor mutation load, DNA mismatch repair pathway gene mutations, and the degree of immune cell infiltration in tumors in patients with non-small cell lung cancer application.

The present invention provides methods for increasing the sensitivity of a tumour to immunotherapy, chemotherapy or radiotherapy by administering an effective amount of an oligonucleotide that inhibits the binding of miR-27a, or a variant thereof, to its target mRNA. Oligonucleotides used in the invention are typically in the form of a blockmirs used as an adjunctive therapy to inhibit tumour growth, normalise and / or improve function of tumour vasculature, and / or promote immune cell infiltration of tumours.